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ABSTRACT
Objective The aim was to determine the prevalence of
small-bowel neoplasia in asymptomatic patients with
Lynch syndrome (LS) by video capsule endoscopy (VCE).
Design After obtaining informed consent,
asymptomatic proven gene mutation carriers aged 35–
70 years were included in this prospective multicentre
study in the Netherlands. Patients with previous small-
bowel surgery were excluded. After bowel preparation,
VCE was performed. The videos were read by two
independent investigators. If significant lesions were
detected, an endoscopic procedure was subsequently
performed to obtain histology and, if possible, remove
the lesion.
Results In total, 200 patients (mean age 50 years
(range 35–69), M/F 88/112), with proven mutations
were included. These concerned MLH1 (n=50), MSH2
(n=68), MSH6 (n=76), PMS2 (n=3) and Epcam (n=3)
mutation carriers. In 95% of the procedures, caecal
visualisation was achieved. Small-bowel neoplasia was
detected in two patients: one adenocarcinoma
(TisN0Mx) and one adenoma, both located in the
duodenum. In another patient, a duodenal cancer
(T2N0Mx) was diagnosed 7 months after a negative
VCE. This was considered a lesion missed by VCE.
All three neoplastic lesions were within reach of a
conventional gastroduodenoscope. All patients with
neoplasia were men, over 50 years of age and without a
family history of small-bowel cancer.
Conclusions The prevalence of small-bowel neoplasia
in asymptomatic patients with LS was 1.5%. All
neoplastic lesions were located in the duodenum and
within reach of conventional gastroduodenoscopy.
Although VCE has the potential to detect these
neoplastic lesions, small-bowel neoplasia may be missed.
Trial registration number NCT00898768.
INTRODUCTION
Cancer of the small intestine is uncommon. One of
the conditions associated with an increased risk of
small-bowel cancer (SBC) is Lynch syndrome (LS),
formerly known as hereditary non-polyposis colo-
rectal cancer.1 LS is caused by a germline mutation
in one of the mismatch repair (MMR) genes
MLH1, MSH2/Epcam, MSH6 or PMS2. It is clin-
ically characterised by a high lifetime risk of colo-
rectal cancer, but also of various extracolonic
malignancies. These include cancer of the
endometrium, ovary, stomach, urinary tract, small
bowel, biliary tract, pancreas, brain and skin.2
For some malignancies of the tumour spectrum
in LS, international guidelines recommend surveil-
lance. Surveillance colonoscopy is recommended
every 1–2 years starting from the age of 20–25
years.3 4 Regular colonoscopy reduces the risk of
developing colorectal cancer and reduces the mor-
tality from colorectal cancer.5–7 Also recommended
are annual transvaginal ultrasound and endometrial
sampling of the uterus for endometrial cancer,
urine analysis with cytology for urinary tract cancer
and screening mutation carriers for the presence of
an Helicobacter pylori infection with subsequent
eradication, but evidence supporting surveillance of
extracolonic malignancies is scarce.2 4
Up till now, surveillance of the small bowel is not
recommended in mutation carriers. This may be
Significance of this study
What is already known on this subject?
▸ Lynch syndrome (LS) is associated with an
increased risk of small-bowel cancer.
▸ Up till now, surveillance of the small bowel is
not recommended due to limited options for
visualisation of the small bowel in the past.
▸ Video capsule endoscopy allows for surveillance
of the small bowel.
▸ Robust data on the prevalence of small-bowel
neoplasia in LS are lacking.
What are the new findings?
▸ The prevalence of small-bowel neoplasia in
asymptomatic patients with LS is 1.5%.
▸ All neoplastic lesions were located in the
duodenum and within reach of a conventional
gastroduodenoscope.
▸ Video capsule endoscopy has the potential to
safely detect neoplastic lesions, but may also
miss neoplastic lesions.
How might it impact on clinical practice in
the foreseeable future?
▸ This study will help gastroenterologists in the
decision-making process with respect to
small-bowel surveillance in patients with LS.
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partly due to limited options for visualisation of the small bowel
in the past.8 Introduction of small-bowel video capsule endos-
copy (VCE) enables visualisation and thereby also surveillance
of the small bowel. This raises the question whether surveillance
of patients with LS for small-bowel neoplasia may now be
feasible.
Before implementing a surveillance programme, in general,
the target group needs to have an increased lifetime risk for a
certain condition. In LS, the estimated lifetime risk of develop-
ing SBC is 4.2%, corresponding to a relative risk of more than
100 compared with the general population.8 9 SBC also occurs
at an earlier age in mutation carriers compared with the general
population.10 However, exact data on prevalence and incidence
of SBC in LS are still unknown. Before statements can be made
concerning surveillance of SBC in patients with LS, it is import-
ant to obtain more robust data about SBC prevalence and
incidence.
The aim of this study was to determine the prevalence of
small-bowel neoplasia by VCE in asymptomatic patients with LS.
MATERIALS AND METHODS
Study design
This study was a nationwide prospective multicentre trial in the
Netherlands to determine the prevalence of small-bowel neopla-
sia by VCE in asymptomatic patients with LS. The study was
registered in the ClinicalTrials.gov registry with identifier
NCT00898768. The study protocol was approved by the local
medical ethical committee of the University Medical Center
Groningen and all participating centres. Patients were included
between March 2009 and January 2013.
Study population
The study population consisted of asymptomatic proven carriers
of a MMR-gene mutation (MLH1, MSH2/Epcam, MSH6 or
PMS2) between the age of 35 and 70 years. Exclusion criteria
were (1) previous small-bowel surgery or large-bowel surgery
involving the ileocaecal valve, (2) a strong clinical suspicion of
small-bowel stricture, (3) pregnancy and (4) presence of any psy-
chological, familial, sociological or geographical condition
potentially hampering compliance with the study protocol and
follow-up schedule.
Study procedures
Patients fulfilling the inclusion criteria were identified by the
gastroenterologists of each participating hospital. A written
informed consent was obtained from these patients. VCE proce-
dures in all participating centres were performed according to a
standardised protocol. Bowel preparation based on polyethylene
glycol electrolyte solution was given, starting the day before the
procedure. The video capsules used were supplied by Given
Imaging (SBII, Yoqneam, Israel), with a recording time of 8 h.
All VCE recordings were reviewed by two experienced gastro-
enterologists; the local VCE-responsible gastroenterologist and
the study coordinator ( JJK). This double revision method was
chosen as a control to limit the possibility of missing an import-
ant lesion and purpose was not to study the concordance
between the observers. The most relevant findings obtained
from VCE were documented and categorised according to
standard terminology as angiectasia(s); ulcer(s); bleeding of
unknown origin; erosion(s) and polyp(s)/tumour(s).11 Other
VCE findings including quality of bowel preparation, gastric
transit time (GTT), small-bowel transit time (SBTT) and com-
pleteness of the VCE procedure were also recorded. GTT was
defined as the interval in minutes between the entrance of the
capsule into the stomach and the first image of the duodenum.
SBTT was defined as the interval in minutes between the
entrance into the duodenum and the entrance into the caecum.
VCE was considered complete if caecal visualisation was
achieved. To evaluate the quality of bowel preparation, a semi-
quantitative evaluation by means of a grading scale was used.
The small-bowel preparation was scored as poor, fair or good.
Small-bowel preparation was defined as good if the mucosa was
generally clean with no or minimal residual fluid or debris; fair,
if the visualisation of the mucosa was impaired because of mod-
erate fluid and debris; and poor if the mucosa visualisation was
highly limited because of excessive residual fluid and debris.
If polyps with an estimated size of at least 1 cm or
malignant-appearing lesions were seen on the VCE recordings,
additional endoscopic procedures were performed. When
lesions were identified in the duodenum, a gastroduodenoscopy
was performed. Otherwise, balloon-assisted enteroscopy was
planned. The aim of these endoscopic procedures was to obtain
histology and, if possible, remove the lesion. If endoscopic
resection was not possible, a tattoo mark was placed to facilitate
surgical identification and resection. For balloon-assisted entero-
scopy, patients were fasting from midnight if an oral/antegrade
approach was used, and received bowel preparation in case of
an anal/retrograde approach. The choice of route (antegrade or
retrograde) was determined by the VCE findings. If abnormal-
ities were seen within the first two-thirds of the capsule record-
ing time, the antegrade approach was chosen. In other cases, the
retrograde approach was chosen. When no lesions were found
with one approach, the maximum point of introduction was
marked with ink. Subsequently, the alternative approach was
chosen in a second procedure if considered necessary.
Since this study is the first part of a longitudinal study, every
patient remains in follow-up for 2 years. After 2 years, each
patient participates in a second VCE examination.
Endpoints
The primary endpoint of this study was the number of patients
with neoplastic small-bowel lesions. Lesion characteristics
recorded were morphology according to the Paris Classification,12
size, location and histology. Secondary endpoint was the number
of complications following capsule endoscopy and subsequent
endoscopic procedures.
Statistical analysis
Statistical analysis was done with SPSS V.20.0. Descriptive statis-
tics were used to determine demographic characteristics and to
analyse VCE results.
RESULTS
Two hundred and one patients were included. After informed
consent, one patient withdrew because of depression. Two
hundred patients with a mean age of 50 years (range 35–69
years) were analysed. Table 1 shows the demographic character-
istics of the included patients.
Performance VCE
The small bowel was completely examined in 190 patients
(95%). Mean gastric and SBTTs were 40 (1–435) and 232 (14–
479) minutes, respectively. In the majority of cases, bowel prep-
aration was good (81%), while bowel preparation was fair in
16% and poor in 3%. Besides polypoid lesions other lesions
were demonstrated as well: lymfangiectasia (n=17), angiodys-
plasia (n=7), ulceration (n=6) and hypertrophic Brunner’s
gland (n=5).
Endoscopy
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Prevalence of neoplasia
Possible polypoid or malignant-appearing lesions were suspected
by VCE in 23 patients. All abnormalities were protruding-type
lesions. Six of these lesions were considered insignificant
because of small size (estimated smaller than 1 cm) and an endo-
scopic aspect resembling lymfangiectasia(s). No further investi-
gations were performed in these six patients.
The remaining 17 patients with possible polypoid lesions on
VCE all subsequently underwent an endoscopic procedure
within 3 months of the VCE procedure, except for one patient.
In this patient, balloon-assisted enteroscopy was not available at
the time; instead MR enteroclysis was performed, which
showed no abnormalities. Ten patients underwent a gastroduo-
denoscopy and six underwent balloon-assisted enteroscopy
(table 2 and figure 1).
In eight of the 16 patients (50%), lesions were found that
matched the findings of VCE. Histological examination of these
eight lesions revealed two neoplastic lesions: one carcinoma and
one adenoma. All other histological diagnoses were non-
neoplastic (three cases of hypertrophic Brunners’ glands, two
cases of lymphoid hyperplasia and one case of heterotopic
gastric mucosa). In eight patients, no lesions were encountered.
In one, retrograde balloon-assisted enteroscopy was performed
after the oral approach, also showing no lesions. In the other
seven patients, no further investigations were carried out. The
VCE findings were considered as falsely positive, because defin-
itely the whole area, including the lesion location seen on VCE,
was thoroughly examined during the endoscopy.
Characteristics of patients with small-bowel neoplasia
Neoplasia was diagnosed in two patients by VCE (figure 2).
Both patients were men over 50 years of age, without a family
history of SBC. Different MMR gene mutations were involved:
MSH6 and MSH2. Both neoplastic lesions were located in the
duodenum and were within reach of a conventional
gastroduodenoscope.
The carcinoma (TisN0Mx) was removed by performing a
pylorus preserving pancreaticoduodenectomy; the low-grade
dysplastic tubulovillous adenoma was removed endoscopically.
Follow-up
During follow-up, it became clear that one SBC was missed
with VCE. In one MLH1 mutation carrier, a 65-year-old man,
SBC was diagnosed during follow-up. Seven months after a
negative VCE procedure, a gastroduodenoscopy was performed
because of unexplained weight loss. On this occasion, a semicir-
cular ulcerative lesion was found in the duodenum. Histology
revealed adenocarcinoma (T2N0Mx). Reassessment of the
earlier VCE recording by two gastroenterologists again revealed
no abnormalities. The patient underwent surgery and unfortu-
nately died of postoperative complications.
Positive and negative predictive value
In two of the 23 patients with polyps or malignant appearance
on VCE, small-bowel neoplasia was present, corresponding to a
positive predictive value of 9%. Assuming that all capsule endos-
copy procedures with normal findings were truly negative except
for the one reported, the negative predictive value was 99%.
Table 2 Results of further procedures investigating possible suspicious lesions found on VCE
Age, sex Mutation VCE finding* Location Procedure Final diagnosis
52, M MSH2 Thickened fold Duodenum Gastroduodenoscopy Adenocarcinoma
61, M MSH6 Polyp <5 mm Duodenum Gastroduodenoscopy Tubulovillous adenoma
52, F MSH6 Polyp <5 mm Jejunum DBE antegrade No abnormalities
46, F MSH2 Polyp 6–9 mm Jejunum DBE retrograde and antegrade No abnormalities
57, M MLH1 Polyp <5 mm Duodenum DBE antegrade Lymfoid hyperplasia
44, F MLH1 Polyp 6–9 mm Duodenum Gastroduodenoscopy Brunner’s gland
48, M MLH1 Polyp <5 mm Duodenum Gastroduodenoscopy Brunner’s gland
39, M MSH6 Lymphoid hyperplasia Jejunum DBE antegrade No abnormalities
40, M MLH1 Polyp <5 mm Jejunum DBE antegrade No abnormalities
61, M MSH6 Polyp <5 mm Jejunum DBE antegrade No abnormalities
37, F MLH1 Polyp 6–9 mm Jejunum Gastroduodenoscopy No abnormalities
60, M MSH6 Polyp 6–9 mm Duodenum Gastroduodenoscopy Inflammation tissue
40, M MLH1 Polyp 10 mm Duodenum Gastroduodenoscopy Heterotopic gastric mucosa
54, F MLH1 Haematin pigmentation Duodenum Gastroduodenoscopy No abnormalities
40, M MSH2 Polyp <5 mm Duodenum Gastroduodenoscopy No abnormalities
54, F MSH6 Polyp <5 mm Stomach Gastroduodenoscopy No abnormalities




MRI enteroclysis No abnormalities
*According to the Paris Classification.
DBE, double balloon enteroscopy; VCE, video capsule endoscopy.
Table 1 Patient characteristics (n=200)
Age (mean, range, in years) 50.4 (35–69)
Male sex, n (%) 88 (44)






Positive family history for SBC, n (%) 9 (5)
Personal history of neoplasia, n (%) 50 (25)
SBC, small-bowel cancer.
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Complications
One complication was observed. One patient had capsule reten-
tion 2 weeks after the VCE examination as was demonstrated
on abdominal X-ray. A few days later a retrograde balloon-
assisted enteroscopy was performed. The capsule was not
encountered. When the X-ray was repeated, the capsule was not
visible anymore. Apparently, the capsule had been discharged in
the period between the first X-ray and the enteroscopy. No com-
plications were observed from the 16 endoscopic procedures
performed in this study.
DISCUSSION
The aim of the present study was to determine, by VCE, the
prevalence of small-bowel neoplasia in asymptomatic LS muta-
tion carriers . We found that VCE revealed small-bowel neopla-
sia in two of 200 persons, and it became apparent during the
study period that a third patient had SBC which had not been
seen with the VCE 7 months before. Overall, the prevalence of
small-bowel neoplasia was 1.5%. All neoplastic lesions were
found in men over 50 years of age and were located in the duo-
denum, within reach of a conventional gastroduodenoscope.
Two previous studies evaluated the performance of VCE in
LS. Saurin et al13 investigated the prevalence of small-bowel
neoplasia in asymptomatic patients with LS by both VCE and
CT enteroclysis. In 35 proven gene carriers, histologically con-
firmed small-bowel neoplasms were detected by VCE in three
patients (8.6%): one carcinoma and two adenomas. CT entero-
clysis detected the carcinoma, but missed the two adenomas.
Based on these results, the authors concluded that surveillance
for small-bowel neoplasia in LS by VCE might be efficient.13
The difference between their and our results may well be due to
the much smaller sample size of their study. Another possible
explanation might be that a relatively high number of MSH6
mutation carriers was included in the present study, as previous
Figure 2 Small-bowel neoplasia detected by video capsule endoscopy (VCE). (A) VCE image of the detected adenoma. (B) Gastroduodenoscopy
image of the same adenoma. (C) VCE image of the detected carcinoma. (D) Gastroduodenoscopy image of the same carcinoma.
Figure 1 Consort diagram.
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data suggest a lower incidence of SBC in MSH6 mutations car-
riers than in those with a MLH1 or MSH2 mutation.8
Another recent study evaluated the use of VCE combined
with non-endoscopic techniques (mainly MR, and in some
patients CT enteroclysis) to detect small-bowel neoplasia. In the
46 asymptomatic proven mutation carriers that were included in
this study, one SBC was detected (2%).14
Taking the three studies together, the prevalence of small-
bowel neoplasia in asymptomatic patients with LS was 2.5%.
Despite the large number of patients included in this pro-
spective trial, this study has limitations that could potentially
influence the results. First, for the assessment of neoplastic
lesions in the small bowel, no standard reference was available.
Intraoperative panenteroscopy would provide such information,
but the invasive nature of this procedure in relation to the prob-
ably not even present lesion was considered disproportional
and, therefore, was considered not feasible. We did not include
a radiological method since no radiological modality demon-
strated a significantly higher sensitivity or specificity than VCE
in detecting neoplastic lesions in the small bowel. Of various
radiological imaging techniques, CT enterography appears to
have a good sensitivity to detect small-bowel tumours.15 In
patients with familial adenomatous polyposis, VCE has demon-
strated higher sensitivity for polyps than radiological investiga-
tions such as small-bowel follow-through and MR
enteroclysis.16 A recent report indicated that CT enterography
may be more sensitive than VCE in the detection of small-bowel
tumours.17 However, this was not demonstrated in patients with
LS.13 In a retrospective study, MR enteroclysis was shown to
have a high overall diagnostic accuracy and to be more specific
than VCE.18 19
Second, it is known that VCE may miss small-bowel tumours,
especially when located in the duodenum.17 20–23 This also
appeared to be the case in the present study. Therefore, one
might speculate that because of the possibility of false negative
results, the true prevalence of small-bowel neoplasia may be
higher than we demonstrated here.
Third, the distribution of small-bowel neoplasia in our study,
exclusively found in the duodenum, is not representative of the
real distribution of small-bowel neoplasia. In a review consider-
ing all described small-bowel tumours in LS, 43% of the SBCs
were located in the duodenum, 37% in the jejunum and 20% in
the ileum.8 Based on this, one could have expected to detect
neoplasia in the jejunum and ileum as well. The quality of
bowel visualisation in VCE is generally higher in the proximal
small bowel than in the distal small bowel,24 25 so this may have
influenced the zero detection rate in the distal part of the small
bowel in our study. On the other hand, we chose to use bowel
preparation with polyethylene glycol to optimise the diagnostic
yield and to minimise this possible bias.25 26 Bowel preparation
was considered good in the great majority of the VCE proce-
dures. Therefore, we think the quality of visualisation of the
distal small bowel was not an influential factor on the distribu-
tion of neoplastic lesions as found.
Finally, capsule endoscopy in our study was associated with
some false positive findings. It is known that abnormalities seen
on capsule endoscopy are not always reproduced in subsequent
endoscopic investigations.27 It must be emphasised that all cases
where endoscopy revealed no abnormalities, were cases in
which the initial capsule endoscopy findings were relatively non-
suspicious and in those cases, further investigations were consid-
ered not to be warranted.
Before statements can be made concerning the value of
small-bowel surveillance in asymptomatic patients with LS, it
is important to obtain more data about incidence of SBC in
LS. All patients included in this study will undergo a second
capsule endoscopy procedure 2 years after the first procedure
as part of a follow-up study which will provide additional
data.
If surveillance subsequently is considered, the question is
which surveillance instrument should be used. One strong point
of VCE is its safety. In our study, only one patient experienced
capsule retention which finally did resolve without an endo-
scopic intervention. In previous large studies, capsule retention
occurred in 0.75%–2.5% of cases.28 No other complications,
like bleeding or perforation were observed. VCE, therefore, has
the potential to be a safe surveillance instrument in LS.
However, in the present study, all detected neoplastic lesions
were within reach of a conventional gastroduodenoscope. One
strong point of a conventional gastroduodenoscope is the possi-
bility to thoroughly examine the gastric mucosa as well. Some
authors already recommend to consider surveillance gastroduo-
denoscopy in LS because of substantial risks of developing
gastric cancer.29 Because of these advantages of gastroduodeno-
scopy, and given the fact that the retrospectively demonstrated
overall miss rate of small-bowel neoplasia of VCE is about
10%,30 it may be worthwhile to determine the role of gastro-
duodenoscopy as a surveillance tool in LS for small-bowel neo-
plasia, also in view of cost effectiveness. For clinical practice at
this moment, our data suggest no role for surveillance of the
small bowel in LS by VCE.
In conclusion, the prevalence of small-bowel neoplasia in
asymptomatic LS mutation carriers was 1.5%, and two out of
three lesions were detected by VCE. These neoplastic lesions
were detected in men over 50 years of age. All lesions were
located in the duodenum and within reach of a conventional
gastroduodenoscope. VCE has the potential to safely detect neo-
plastic lesions at an early stage, although small-bowel neoplasia
may be missed.
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